BI 1810631
Boehringer Ingelheim
['lung', 'lcsm,(-blcsm)', 'bi 1810631', 'solid tumor']
#asco23 #lungcancer #lcsm dr. john heymach
phase i beamion lung 1 trial of bi 1810631, a her2 tyrosine kinase inhibitor (tki), as monotherapy in patients (pts) with advanced/metastatic solid tumors with her2 aberrations abstract: 8545| poster bd #: 172 
Working to improve and save lives by funding groundbreaking research for the prevention, diagnosis, treatment and cure of lung cancer.